Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of “Hold” from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX) has been given a consensus rating of “Hold” by the nine analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $22.78.

Several brokerages have recently commented on PCRX. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price objective for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC increased their price target on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Barclays lowered their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a report on Tuesday, November 12th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th.

Institutional Investors Weigh In On Pacira BioSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PCRX. Truist Financial Corp purchased a new position in shares of Pacira BioSciences in the second quarter valued at about $423,000. SG Americas Securities LLC grew its stake in shares of Pacira BioSciences by 96.4% in the third quarter. SG Americas Securities LLC now owns 25,254 shares of the company’s stock worth $380,000 after purchasing an additional 12,396 shares during the last quarter. CWM LLC increased its holdings in Pacira BioSciences by 713.6% during the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after purchasing an additional 5,716 shares during the period. Inspire Investing LLC raised its position in Pacira BioSciences by 122.7% during the 3rd quarter. Inspire Investing LLC now owns 27,474 shares of the company’s stock valued at $413,000 after purchasing an additional 15,138 shares during the last quarter. Finally, Wedge Capital Management L L P NC raised its position in Pacira BioSciences by 131.9% during the 3rd quarter. Wedge Capital Management L L P NC now owns 119,447 shares of the company’s stock valued at $1,798,000 after purchasing an additional 67,947 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Trading Down 0.4 %

NASDAQ PCRX opened at $27.13 on Thursday. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The stock’s 50-day simple moving average is $21.56 and its two-hundred day simple moving average is $18.00. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $31.67. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -13.36 and a beta of 0.80.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.